Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €bn | 17.9 | 17.6 | 19.4 | 19.5 | 19.3 | 19.6 | 19.4 | 19.4 |
| Operating profit | €bn | 1.83 | 2.08 | ||||||
| Net profit | €bn | 1.16 | 0.97 | 0.67 | 0.50 | 0.54 | 0.98 | 0.94 | 1.20 |
| EPS reported | € | 3.36 | 3.32 | ||||||
| Operating cashflow per share | € | 9.21 | 10.54 | ||||||
| Capex per share | € | 3.14 | 3.90 | ||||||
| FCF per share | € | 6.06 | 6.65 | ||||||
| Free cash flow | €bn | 1.77 | 1.78 | ||||||
| Net debt | €bn | 5.58 | 6.12 | ||||||
| Book value equity | €bn | 13.3 | 12.6 | ||||||
| Book value per share | € | 45.71 | 46.78 | ||||||
| Number of shares | m | 291.19 | 268.44 | ||||||
| DPS (TTM paid) | € | 1.49 | 1.49 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 12.13 | 11.30 | ||||||
| P/B LTM | x | 0.89 | 0.79 | ||||||
| P/S LTM | x | 0.60 | 0.51 | ||||||
| P/FCF LTM | x | 6.72 | 5.59 | ||||||
| EV/EBITDA LTM | x | 6.31 | 4.53 | ||||||
| EV/Sales LTM | x | 1.07 | 0.83 | ||||||
| Earnings Yield LTM | % | 8.24% | 8.85% | ||||||
| FCF Yield | % | 14.88% | 17.88% | ||||||
| Quality | |||||||||
| ROE | % | 7.35% | 7.21% | ||||||
| ROIC | % | 5.34% | 6.21% | ||||||
| Operating margin | % | 9.31% | 10.69% | ||||||
| Gross margin | % | 25.62% | 26.36% | ||||||
| FCF/Sales | % | 9.00% | 9.19% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +83.61% | +47.56% | ||||||
| Sales Growth YoY | % | +1.51% | -0.46% | ||||||
| Net Income Growth YoY | % | +81.81% | +42.86% | ||||||
| FCF Growth | % | +4.67% | -13.10% | ||||||
| Operating Profit Growth | % | +31.20% | +40.51% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 3.56% | 3.97% | ||||||
| Dividend Growth | % | +3.47% | +3.47% | ||||||
| Payout Ratio | % | 43.18% | 0.00% | ||||||
| FCF/Debt | x | 0.16 | 0.16 | ||||||
| Net Debt/EBITDA | x | 2.76 | 2.79 | ||||||
| EBIT/Net interest | x | 4.74 | 5.42 | ||||||
| Net debt/market cap | % | 47.00% | 61.29% | ||||||
| Net debt/Equity | x | 0.42 | 0.49 | ||||||
| Gross debt/equity | x | 0.81 | 0.87 | ||||||
ETFs that hold Fresenius Medical Care
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Dimensional - International Small Cap Value ETF | DISV | 9 | 0.62% |
| Deka DAXplus Maximum Dividend UCITS ETF | EL4X.DE | 6 | 6.73% |
| First Trust Germany AlphaDEX Fund | FGM | 8 | 3.51% |
| Pzena U.S. Large Cap Value ETF | PZLV | 10 | 3.06% |
Funds with Fresenius Medical Care among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Fresenius Medical Care AG & Co. KGaA (FME.DE)
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Dimensional - International Small Cap Value ETF | DISV | 9 | 0.62% |
| Deka DAXplus Maximum Dividend UCITS ETF | EL4X.DE | 6 | 6.73% |
| First Trust Germany AlphaDEX Fund | FGM | 8 | 3.51% |
| Pzena U.S. Large Cap Value ETF | PZLV | 10 | 3.06% |
Funds with Fresenius Medical Care among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free